ROCHESTER, Minn. — A Mayo Clinic-led group of researchers has discovered three subgroups of a single type of non-Hodgkin lymphoma that have markedly different survival rates. These subgroups could not be differentiated by routine pathology but only with the aid of novel genetic tests, which the research team recommends giving to all patients with ALK-negative anaplastic large-cell lymphoma (ALCL). Findings are published in the journal Blood.
Recent Posts
- Ketogenic Diet Enhances CAR-T Cancer Therapy
- Socioeconomic Barriers Limit Access to Lifesaving Stem Cell Transplants in AML
- Newly discovered mechanism in the cell’s energy factory can lead to new treatment of muscle disorders
- New drug tested to reduce side effect of ‘half-matched’ stem cell transplants
- Gene and Cell Therapies Take Aim at Parkinson’s Disease
- Health Net grant for UC Davis Stem Cell Program to improve access to CAR T-cell therapy